Development of lipogenesis inhibitors for tumor regression in renal cell carcinoma and other MYC-driven cancers
Ended Project Grant Awarded Last action
- Award ID
- R43CA256978
- Recipient
-
Bacchus Therapeutics Inc. UEI EWCHMK9ZL174
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,216,296
Award facts
- Assistance listing
- 93.395 Cancer Treatment Research
- Completion date
- Originally
- Funding
-
- $810,864.00 Federal
- $405,432.00 Non-federal
- Place of performance
- California, USA
Award details come from USAspending.gov.
Description
- Abstract
- Over 400,000 new cases of renal cell carcinoma (RCC) are detected annually worldwide. One-fourth of these patients are already in advanced stages when diagnosed; with current therapies, their predicted 5-year survival rate is only 12%. To help curtail this loss of life, bacchus therapeutics has created a family of novel molecules that cause regression of tumors in preclinical animal models of RCC. These potential therapeutics provided long- term survival, rather than merely delaying tumor growth. These compounds also showed potency against other cancers driven by the MYC oncogene, including hepatocellular carcinoma and b-cell lymphoma. The goal of the proposed phase i sbir project is to characterize the biochemical traits and cytotoxicity of 7 candidate molecules, which will determine a lead candidate for development into an effective drug against RCC. Initial studies will define the solubility of the molecules, as well as specificity for their target enzyme. Additional work will evaluate their relative toxicity to RCC versus normal cell lines. Based on these results, the candidate with the highest specific potency will be tested in mouse models of RCC, using patient-derived xenografts that express either high or low levels of MYC. Following the successful completion of these aims, we will seek phase II sbir funding to undertake studies that will enable investigational new drug development. Through partnering or licensing, we plan to commercialize the lead compounds as a completely new therapeutic agent against advanced RCC. Future work will evaluate this molecule or related analogs for treatment of other MYC-driven cancers.
Transactions
| Action | Federal | Non-federal | Date |
|---|---|---|---|
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $405,432 | $0 | |
| Original award | $405,432 | $405,432 |
Quick answers
Who received award R43CA256978?
R43CA256978 was awarded to Bacchus Therapeutics Inc. by National Cancer Institute (National Institutes of Health) on August 1, 2021.
How much is award R43CA256978 worth?
$1,216,296 has been obligated on R43CA256978: $810,864 in federal funding and $405,432 in non-federal funding.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award